IQVIA Holdings Inc.(IQV) Stock Research - Grey Stern Research
Loading...

IQVIA Holdings Inc. (IQV) Stock Analysis

$199.93 (-1.59%)

IQV Financial Performance


Use the table below to view IQVIA Holdings Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $199.93 -
52 Week Low $187.62 -
52 Week High $261.73 -
Market Cap $36.3 Billion 1/12
Gross Margin 35% 7/12
Profit Margin 7% 7/12
EBITDA margin 20% 5/12
Q3 - 2024 Revenue $3.9 Billion 1/12
Q3 - 2024 Earnings $285.0 Million 1/12
Q3 - 2024 Free Cash Flow $1.0 Million 1/12
Trailing 4 Quarters Revenue $15.3 Billion 1/12
Trailing 4 Quarters Earnings $1.4 Billion 1/12
Quarterly Earnings Growth -6% 8/12
Annual Earnings Growth 18% 2/12
Quarterly Revenue Growth 4% 6/12
Annual Revenue Growth 3% 3/12
Cash On Hand $1.6 Billion 1/12
Short Term Debt $1.2 Billion 2/12
Long Term Debt $12.5 Billion 1/12

IQVIA Holdings Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare IQVIA Holdings Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 25.83 9/12
PS 2.37 10/12
PB 5.21 5/12
PC 23.08 7/12
Liabilities to Equity 2.90 1/12
ROA 0.05 5/12
ROE 0.20 5/12
Current Ratio 1.34 11/12
Quick Ratio 0.08 9/12
Long Term Debt to Equity 1.79 1/12
Debt to Equity 1.97 1/12
Burn Rate 3.03 5/12
Cash to Cap 0.04 5/12
CCR 3.54 2/12
EV to EBITDA 60.67 7/12
EV to Revenue 3.16 9/12

Company Details

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

CEO: Mr. Ari Bousbib

Website: https://www.iqvia.com

Address: 4820 Emperor Blvd Durham, NORTH CAROLINA

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

IQVIA Holdings Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to IQVIA Holdings Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Syneos Health, Inc. SYNH $4.5 Billion
Qiagen N.V. QGEN $9.6 Billion
Laboratory Corporation of America Holdings LH $19.6 Billion
IDEXX Laboratories, Inc. IDXX $35.0 Billion
Waters Corporation WAT $22.6 Billion
Charles River Laboratories International, Inc. CRL $9.8 Billion
Mettler-Toledo International Inc. MTD $26.3 Billion
ICON Public Limited Company ICLR $17.3 Billion
Medpace Holdings, Inc. MEDP $10.6 Billion
Neogen Corporation NEOG $2.7 Billion
Twist Bioscience Corporation TWST $3.0 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
IQV Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 3.9 Billion $285.0 Million
Q2 2024 $ 3.8 Billion $363.0 Million
Q1 2024 $ 3.7 Billion $288.0 Million
Q4 2023 $ 3.9 Billion $469.0 Million
Q3 2023 $ 3.7 Billion $303.0 Million
Q2 2023 $ 3.7 Billion $297.0 Million
Q1 2023 $ 3.7 Billion $289.0 Million
Q3 2022 $ 3.6 Billion $283.0 Million

View All

IQV Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $1.6 Billion $27.2 Billion $13.7 Billion $7.0 Billion
Q2 2024 $1.5 Billion $26.4 Billion $13.5 Billion $6.7 Billion
Q1 2024 $1.4 Billion $26.6 Billion $13.7 Billion $6.3 Billion
Q4 2023 $1.4 Billion $26.7 Billion $13.9 Billion $6.1 Billion
Q3 2023 $1.2 Billion $26.0 Billion $13.8 Billion $5.8 Billion
Q2 2023 $1.4 Billion $26.0 Billion $14.0 Billion $5.7 Billion
Q1 2023 $1.5 Billion $25.7 Billion $13.4 Billion $5.9 Billion
Q3 2022 $1.3 Billion $24.2 Billion $12.7 Billion $5.3 Billion

View All

IQV Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.0 Billion $288.0 Million $27.0 Million
Q2 2024 $445.0 Million -$143.0 Million $101.0 Million
Q1 2024 $377.0 Million -$145.0 Million $68.0 Million
Q4 2023 $1.2 Billion $470.0 Million $152.0 Million
Q3 2023 $437.0 Million -$146.0 Million -$158.0 Million
Q2 2023 $876.0 Million $0 $876.0 Million
Q1 2023 $253.0 Million -$164.0 Million $278.0 Million
Q3 2022 $698.0 Million -$165.0 Million -$154.0 Million

View All